Spain Turns to Delayed Antibiotics
A national push aims to curb unnecessary treatment while keeping medicine available when infections fail to improve
Spain is preparing to expand delayed antibiotic prescribing across its regional health services, targeting respiratory infections for which doctors cannot immediately determine whether antibiotics are necessary. The approach allows a clinician to issue a prescription but instruct the patient to wait, usually between 24 and 72 hours, and begin treatment only if symptoms persist or worsen.
The Spanish Agency for Medicines and Health Products, known as AEMPS, is working with the country’s autonomous communities and health professionals to map existing practices and extend the system where it is not yet integrated. The national expansion plan forms part of Spain’s strategy against antimicrobial resistance.
Prescription now, treatment only if needed
Delayed prescribing is designed for carefully selected cases in which immediate antibiotic treatment is not clinically required but may become appropriate if an infection develops differently than expected. Many common respiratory illnesses are viral, meaning antibiotics will not treat them.
Under the proposed approach, the prescribing decision remains with the doctor. Patients are given specific instructions about how long to wait, which symptoms to monitor and when to seek further medical attention. It is not a general recommendation to postpone antibiotics or an invitation for patients to diagnose themselves.
Where an electronic prescription system supports the process, access to the medicine can be activated after a defined period. The Valencian Community introduced such a mechanism for mild respiratory infections, allowing prescriptions to become available at pharmacies after 24 or 48 hours. Other regions have protocols, but these are not always integrated centrally into their electronic systems.
This uneven landscape explains why the national working group is important. Spain’s decentralised health system gives regional authorities substantial responsibility for service delivery. A policy may therefore exist on paper while patients, doctors and pharmacists encounter different procedures depending on where they live.
What the clinical evidence shows
A Cochrane review of 12 trials, covering 3,968 participants and analysing prescribing outcomes for 3,750 of them, found that delayed prescriptions substantially reduced antibiotic use compared with immediate treatment.
Across the studies, 93% of participants given an immediate prescription used antibiotics, compared with 29% in the delayed-prescription group and 13% among those given no prescription. Patient satisfaction was broadly similar between delayed and immediate prescribing.
The review found no significant difference in complication rates. For many symptoms, outcomes were also similar, although immediate antibiotics produced modest improvements in some cases of sore throat and middle-ear infection. The evidence was assessed as moderate in certainty, reflecting limitations in how some trials were conducted.
There is another important qualification. The trials measured medicine use, symptoms, complications and satisfaction, but did not directly measure changes in antibiotic resistance. Delayed prescribing can plausibly support resistance-control efforts by reducing unnecessary exposure, but it should not be presented as proof that resistance will decline automatically.
Spain has already reduced consumption
Figures from Spain’s national antibiotic-resistance programme show that human consumption of systemic antibiotics fell by 5.1% in 2025, to 22.94 defined daily doses per 1,000 inhabitants. Consumption was 18.8% lower than in 2015 and 8.4% below its pre-pandemic level in 2019.
Those figures represent progress, but resistant bacterial infections are still associated with an estimated 5,000 deaths each year in Spain. Across Europe, the burden exceeds 35,000 deaths annually. The challenge has consequently moved beyond persuading individual patients to use medicines carefully. It also requires better surveillance, infection prevention, prescribing data and coordination between human and animal health systems.
That broader approach reflects the European drive for prudent antibiotic use, including the EU objective of reducing human antibiotic consumption by 20% by 2030.
Communication will determine whether it works
The practical success of delayed prescribing will depend heavily on communication. Patients need clear explanations of why antibiotics may not help, what worsening symptoms look like and when they should return for medical assessment. Pharmacists must receive consistent information, while doctors need enough consultation time to explain a decision that can otherwise be mistaken for withheld treatment.
Electronic activation may make the system easier to administer, but digital tools cannot replace clinical judgement or accessible follow-up care. Authorities will also need to monitor whether the policy works equally well for older people, patients with language barriers and communities where primary-care appointments are difficult to obtain.
Spain’s initiative offers a practical way to reduce medicine that provides no benefit while preserving rapid access when treatment becomes necessary. Its credibility, however, will rest on transparent implementation and patient safety, not simply on recording fewer antibiotic prescriptions.